Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study-Reference-Cited by-同舟云学术

Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study

Published:2022-10 Issue:5 Volume:20 Page:499.e1-499.e8
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Minato Akinori^ORCID,Furubayashi Nobuki,Harada Mirii,Negishi Takahito,Sakamoto Naotaka,Song Yoohyun,Hori Yoshifumi,Tomoda Toshihisa,Tamura Shingo,Kuroiwa Kentaro,Seki Narihito,Tomisaki Ikko,Harada Kenichi,Nakamura Motonobu,Fujimoto Naohiro

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference28 articles.

1. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017

2. Evaluation of the extent of variant histology in urothelial carcinoma as a predictive marker of clinical outcomes after radical cystectomy;Minato;Cancer Diagn Progn,2021

3. A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy;Mori;J Urol,2020

4. Clinical significance of squamous differentiation in urothelial carcinoma of the bladder;Minato;Cancer Control,2018

5. Prognostic value of squamous differentiation in upper tract urothelial carcinoma treated with radical nephroureterectomy;Minato;Anticancer Res,2022

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study;Current Oncology;2024-02-03

2. Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma;In Vivo;2024

3. Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology;In Vivo;2024

4. Immuno-Oncology Advances in Genitourinary Cancers;American Society of Clinical Oncology Educational Book;2024-01

5. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18